Isomorphic Labs Raises $2.1B Series B to Scale AI Drug Design Engine
Tags AI · Health Tech · Enterprise
Alphabet's Isomorphic Labs, the DeepMind spinout founded by Demis Hassabis, raised $2.1 billion in Series B funding on May 12, 2026, led by Thrive Capital with participation from Alphabet, MGX, Temasek, CapitalG, GV, and the UK Sovereign AI Fund. The London-based company, which previously raised $600M in 2025, will use the capital to scale its AI drug design engine (IsoDDE) and advance its therapeutic pipeline toward clinical trials. Isomorphic's platform builds on AlphaFold's protein structure prediction to model complex biological phenomena across multiple therapeutic areas. The company has strategic research collaborations with Novartis, Eli Lilly, and Johnson & Johnson, and now expects its first clinical trials by the end of 2026.
Technical significance
This is one of the largest-ever funding rounds for an AI biotech company, signaling that sovereign wealth funds and major VCs are placing enormous bets on AI-driven drug discovery. The participation of MGX, Temasek, and the UK Sovereign AI Fund shows this is now a geopolitical investment priority, not just a commercial one. If IsoDDE delivers on its promise, it could compress drug discovery timelines from years to months.